MUMBAI : TB Alliance, a not-for-profit organization, has granted Macleods Pharmaceuticals a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen.
Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis medicine in approximately 140 countries and territories.
“TB Alliance is committed to ensuring an affordable, sustainable and competitive market for all our new TB products,” said Mel Spigelman, president and CEO, TB Alliance.
He stated, “We are proud to partner with Macleods, which has a strong record of delivering high-quality, affordable TB medicines.”
“This important partnership with TB Alliance will ensure accessibility of pretomanid in countries where it is needed the most,” said Vijay Agarwal, business development director at Macleods.
Earlier, TB Alliance has collaborated with Macleods on the introduction of child-friendly formulations of first-line TB medicines. Since the launch in 2015, more than one million treatment courses have been ordered by 94 countries across the globe, which represent approximately 95% of the world childhood TB burden.